Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages
Tumor-associated macrophages play a critical role in breast tumor progression; however, it is still unclear what effector molecular mechanisms they employ to impact tumorigenesis. Ferritin is the primary intracellular iron storage protein and is also abundant in circulation. In breast cancer patients, ferritin is detected at higher levels in both serum and tumor lysates, and its increase correlates with poor clinical outcome. In this study, we comprehensively examined the distribution of ferritin in normal and malignant breast tissue at different stages in tumor development. Decreased ferritin expression in cancer cells but increased infiltration of ferritin-rich CD68-positive macrophages was observed with increased tumor histological grade. Interestingly, ferritin stained within the stroma surrounding tumors suggesting local release within the breast. In cell culture, macrophages, but not breast cancer cells, were capable of ferritin secretion, and this secretion was further increased in response to pro-inflammatory cytokines. We next examined the possible functional significance of extracellular ferritin in a breast cancer cell culture model. Ferritin stimulated the proliferation of the epithelial breast cancer cell lines MCF7 and T47D. Moreover, this proliferative effect was independent of the iron content of ferritin and did not increase intracellular iron levels in cancer cells indicating a novel iron-independent function for this protein. Together, these findings suggest that the release of ferritin by infiltrating macrophages in breast tumors may represent an inflammatory effector mechanism by which ferritin directly stimulates tumorigenesis.
KeywordsFerritin Tumor-associated macrophages Iron Cancer-associated inflammation Breast cancer
The experiments presented in this manuscript comply with the current laws and standards of the USA and have been approved by the institutional review board at Penn State Hershey Medical Center.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 3.Lawson DM, Artymiuk PJ, Yewdall SJ, Smith JM, Livingstone JC, Treffry A, Luzzago A, Levi S, Arosio P, Cesareni G et al (1991) Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature 349(6309):541–544. doi: 10.1038/349541a0 PubMedCrossRefGoogle Scholar
- 10.Alkhateeb A, Leitzel K, Ali SM, Campbell-Baird C, Evans M, Fuchs E, Köstler WJ, Lipton A, Connor J (2012) Elevation in serum inflammatory biomarkers predicts response to trastuzumab-containing therapy. PLoS ONE 7(12):e51379. doi: 10.1371/journal.pone.0051379
- 20.Jezequel P, Campion L, Spyratos F, Loussouarn D, Campone M, Guerin-Charbonnel C, Joalland MP, Andre J, Descotes F, Grenot C, Roy P, Carlioz A, Martin PM, Chassevent A, Jourdan ML, Ricolleau G (2012) Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Int J Cancer 131(2):426–437. doi: 10.1002/ijc.26397 PubMedCrossRefGoogle Scholar
- 24.Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG (2010) Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116(9):1574–1584. doi: 10.1182/blood-2009-11-253815 PubMedCrossRefGoogle Scholar
- 25.Li JY, Paragas N, Ned RM, Qiu A, Viltard M, Leete T, Drexler IR, Chen X, Sanna-Cherchi S, Mohammed F, Williams D, Lin CS, Schmidt-Ott KM, Andrews NC, Barasch J (2009) Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell 16(1):35–46. doi: 10.1016/j.devcel.2008.12.002 PubMedCrossRefGoogle Scholar
- 27.Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, Santambrogio P, Arosio P, Ramm GA (2009) Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 49(3):887–900. doi: 10.1002/hep.22716 PubMedCrossRefGoogle Scholar
- 29.Pinnix ZK, Miller LD, Wang W, D’Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM (2010) Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2(43):43ra56. doi: 10.1126/scisignal.3001127
- 34.DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1(1):54–67. doi: 10.1158/2159-8274.CD-10-0028 PubMedCrossRefGoogle Scholar
- 44.Cozzi A, Corsi B, Levi S, Santambrogio P, Biasiotto G, Arosio P (2004) Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood 103(6):2377–2383. doi: 10.1182/blood-2003-06-1842 PubMedCrossRefGoogle Scholar
- 45.Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11(12):1586–1591Google Scholar
- 46.Cotterchio M, Kreiger N, Sloan M, Steingart A (2001) Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomark Prev 10(11):1213–1217Google Scholar
- 47.Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119(4):529–542. doi: 10.1016/j.cell.2004.10.017 PubMedCrossRefGoogle Scholar